Recently, biologics such as UST, Vedolizumab (VDZ, Anti-α4β7) and TNF-a inhibitors Infliximab (IFX) and Golimumab (GLM) have been approved for treating ulcerative colitis and proposed as first-line agents (16). The gene discussed is TNF; the disease is ulcerative colitis.